Tesamorelin (Egrifta)

• Label dose, 2 mg single-dose vialrecommended

  Reproduces the Egrifta SV label dose for HIV-associated abdominal fat. Each 2 mg vial is a single dose of 0.35 mL (35 units) after 0.5 mL of water.

• Label, Egrifta SV (2 mg vial): 1.4 mg (0.35 mL) subcutaneously once daily.
• Label, Egrifta WR (11.6 mg vial): 1.28 mg (0.16 mL) subcutaneously once daily. The two products are not interchangeable.

Route: Subcutaneous, into the abdomen, rotating sites, at least 5 cm (2 in) from the navel and away from scars or bruises (label).

Timing: Once daily; the label names no time of day.

• SV: add 0.5 mL of the supplied sterile water to the 2 mg vial (4 mg/mL), roll gently for 30 seconds, do not shake; give 0.35 mL immediately and discard the rest.
• WR: add 1.3 mL of the supplied bacteriostatic water to the 11.6 mg vial (8 mg/mL), swirl gently, do not shake.

SV: use immediately, discard unused solution. WR: discard 7 days after mixing; the vial gives 7 daily doses (label).

No off-cycle in the label: continuous daily use.

Why:

• The label advises considering stopping if IGF-1 stays high (e.g. above 3 SDS) or there is no clear efficacy response.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
• The label sources fetched list no combination guidance. Community pairing with other secretagogues was not sourced.

FDA-approved prescription drug for the indication above. Contraindicated with hypothalamic-pituitary axis disruption (hypopituitarism, pituitary tumor or surgery, head irradiation or trauma), active malignancy, hypersensitivity, and pregnancy.

Common side effects:

• Injection-site reactions 17% vs 6% placebo (26 weeks); arthralgia 13% vs 11%; pain in extremity 6% vs 5%; myalgia 6% vs 2%; peripheral edema 6% vs 2% (label).
• Hypersensitivity reactions in about 4% (label).
• HbA1c 6.5% or higher in 5% vs 1% placebo (label).

Stop and call your prescriber if:

• Rash, hives, swelling of face or throat
• Signs of high blood sugar: great thirst, frequent urination
• Vision changes (label: monitor for retinopathy in diabetes)

Labs and monitoring:

• Glucose before starting and periodically during treatment (label).
• IGF-1 during treatment; consider stopping if persistently high, e.g. above 3 SDS. At 26 weeks, 36% had IGF-1 above 3 SDS (label).

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• IGF-1Check itDrug label

  Label says to monitor during therapy and consider stopping if persistently elevated (e.g. above 3 SDS); 36% had IGF-1 SDS above 3 at 26 weeks

  DailyMed: EGRIFTA SV (tesamorelin) label
• Fasting glucose / HbA1cCheck itDrug label

  Evaluate glucose before starting and monitor periodically; HbA1c 6.5% or higher in 5% vs 1% on placebo

  DailyMed: EGRIFTA SV (tesamorelin) label

• DailyMed: EGRIFTA SV (tesamorelin) label, 2 mg vial
• DailyMed: EGRIFTA WR (tesamorelin) label, 11.6 mg vial